Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKG1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKG1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PRKG1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKG1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKG1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKG1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034109 | Colorectum | AD | homotypic cell-cell adhesion | 40/3918 | 90/18723 | 4.37e-07 | 1.67e-05 | 40 |
GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
GO:0042060 | Colorectum | AD | wound healing | 128/3918 | 422/18723 | 2.73e-06 | 7.89e-05 | 128 |
GO:0050878 | Colorectum | AD | regulation of body fluid levels | 108/3918 | 379/18723 | 2.54e-04 | 3.20e-03 | 108 |
GO:0070527 | Colorectum | AD | platelet aggregation | 26/3918 | 67/18723 | 6.20e-04 | 6.48e-03 | 26 |
GO:0090257 | Colorectum | AD | regulation of muscle system process | 73/3918 | 252/18723 | 1.46e-03 | 1.24e-02 | 73 |
GO:0016358 | Colorectum | AD | dendrite development | 69/3918 | 243/18723 | 3.32e-03 | 2.42e-02 | 69 |
GO:00341091 | Colorectum | SER | homotypic cell-cell adhesion | 32/2897 | 90/18723 | 2.23e-06 | 9.31e-05 | 32 |
GO:00420601 | Colorectum | SER | wound healing | 97/2897 | 422/18723 | 2.69e-05 | 7.30e-04 | 97 |
GO:00902571 | Colorectum | SER | regulation of muscle system process | 60/2897 | 252/18723 | 3.28e-04 | 5.22e-03 | 60 |
GO:00163581 | Colorectum | SER | dendrite development | 58/2897 | 243/18723 | 3.82e-04 | 5.81e-03 | 58 |
GO:00430871 | Colorectum | SER | regulation of GTPase activity | 77/2897 | 348/18723 | 5.90e-04 | 8.07e-03 | 77 |
GO:0007162 | Colorectum | SER | negative regulation of cell adhesion | 68/2897 | 303/18723 | 8.02e-04 | 1.01e-02 | 68 |
GO:00508781 | Colorectum | SER | regulation of body fluid levels | 81/2897 | 379/18723 | 1.28e-03 | 1.43e-02 | 81 |
GO:0034110 | Colorectum | SER | regulation of homotypic cell-cell adhesion | 12/2897 | 33/18723 | 2.71e-03 | 2.44e-02 | 12 |
GO:0003012 | Colorectum | SER | muscle system process | 92/2897 | 452/18723 | 2.98e-03 | 2.63e-02 | 92 |
GO:0090075 | Colorectum | SER | relaxation of muscle | 12/2897 | 34/18723 | 3.60e-03 | 3.03e-02 | 12 |
GO:0061041 | Colorectum | SER | regulation of wound healing | 33/2897 | 134/18723 | 3.78e-03 | 3.13e-02 | 33 |
GO:1903034 | Colorectum | SER | regulation of response to wounding | 39/2897 | 167/18723 | 4.73e-03 | 3.72e-02 | 39 |
GO:00705271 | Colorectum | SER | platelet aggregation | 19/2897 | 67/18723 | 5.14e-03 | 3.93e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKG1 | SNV | Missense_Mutation | | c.1434N>G | p.Phe478Leu | p.F478L | Q13976 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PRKG1 | SNV | Missense_Mutation | novel | c.1000G>A | p.Asp334Asn | p.D334N | Q13976 | protein_coding | deleterious(0) | benign(0.054) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PRKG1 | SNV | Missense_Mutation | | c.1061C>T | p.Ala354Val | p.A354V | Q13976 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PRKG1 | SNV | Missense_Mutation | | c.1278G>T | p.Gln426His | p.Q426H | Q13976 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PRKG1 | SNV | Missense_Mutation | | c.1226N>C | p.Lys409Thr | p.K409T | Q13976 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKG1 | SNV | Missense_Mutation | | c.1966N>T | p.Ala656Ser | p.A656S | Q13976 | protein_coding | tolerated(0.68) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRKG1 | SNV | Missense_Mutation | novel | c.859G>T | p.Asp287Tyr | p.D287Y | Q13976 | protein_coding | tolerated(0.09) | benign(0.012) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PRKG1 | SNV | Missense_Mutation | | c.892A>T | p.Thr298Ser | p.T298S | Q13976 | protein_coding | tolerated(0.28) | benign(0) | TCGA-B5-A0JN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
PRKG1 | SNV | Missense_Mutation | | c.1421N>A | p.Ser474Tyr | p.S474Y | Q13976 | protein_coding | tolerated(0.37) | benign(0.005) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PRKG1 | SNV | Missense_Mutation | novel | c.1305N>A | p.Phe435Leu | p.F435L | Q13976 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | GSK-269962A | GSK-269962A | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 249565578 | IPATASERTIB | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 178101884 | GSK-690693 | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | SOTRASTAURIN | SOTRASTAURIN | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | GW843682X | GW843682X | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | inhibitor | 178101945 | | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | LINIFANIB | LINIFANIB | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | TAE-684 | TAE-684 | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | CENISERTIB | CENISERTIB | |
5592 | PRKG1 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME | | PHA-767491 | CHEMBL225519 | |